Intercept to Present at Upcoming Investor Conferences in September
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating at the following upcoming investor conferences:
- Baird 2019 Global Healthcare Conference in New York, NY at 3:10 p.m. ET on Wednesday, September 4, 2019
- Citi 14th Annual Biotech Conference in Boston, MA at 12:45 p.m. ET on Thursday, September 5, 2019
Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Justine O’Malley
+1-646-931-1180
Media inquiries: [email protected]
Source: Intercept Pharmaceuticals, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Update: RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
- BTC Price Prediction: Can It Hit $100k in 2026? While Investors Call Apeing The Next Big Crypto With Its 2400% ROI Potential in Sight
- Renk Group AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, Robert W Baird, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share